FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983456225> ?p ?o ?g. }

• W1983456225 endingPage "1094" @default.
• W1983456225 startingPage "1093" @default.
• W1983456225 abstract "Patients with acute myeloid leukaemia (AML) who have failed haematopoietic stem cell transplantation (HSCT) have a poor prognosis (Webb, 1999). The monoclonal anti-CD33 antibody, gemtuzumab ozogamicin (GO) (Mylotarg, CMA-676; Wyeth Laboratories, Philadelphia, PA, USA) is an emerging therapeutic option for patients with CD33-positive disease (Sievers et al, 2001). We report two patients with recurrent AML who received GO as part of their minimal conditioning before allogeneic HSCT as a second transplantation. The first patient, a 40-year-old woman, was diagnosed with AML [French–American–British (FAB) classification M2] with a normal karyotype in October 2000. First-line chemotherapy led to complete remission (CR) in February 2001. Treatment was accompanied by serious complications and as a result no consolidation therapy was performed. The patient's first relapse was treated with high-dose busulphan (16 mg/kg) and autologous HSCT. Because of further disease progression, allografting from a human leucocyte antigen-matched, unrelated donor was planned. The second patient was a 19-year-old woman who was diagnosed with AML (FAB M4) in April 2001. After achieving CR, the patient underwent myeloablative conditioning therapy (busulphan 16 mg/kg, cyclophosphamide 120 mg/kg) with an allogeneic bone marrow transplantation (BMT) from a matched sibling donor. Unfortunately, only 3 months later, a haematological relapse was diagnosed and a second allogeneic transplant with peripheral blood stem cells (PBSC) from the same donor was scheduled. As a second high-dose conditioning appeared inappropriate for both patients, they received 6 mg/m2 and 3 mg/m2 of mylotarg 21 and 14 d before allogeneic HSCT respectively. Minimal conditioning consisted of 30 mg/m2 fludarabine (on d −3 to −1) and 2 Gy total body irradiation on (d 0) (McSweeney et al, 2001). Granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC were infused on d 0. Patient 1 received PBSC from a matched unrelated donor (5·3 × 106/kg CD34+ cells, 3·1 × 108/kg CD3+ cells). Patient 2 received a PBSC infusion from the original sibling (8·2 × 106/kg CD34+ cells, 4·3 × 108/kg CD3+ cells). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin A (CsA) and mycophenolate mofetil (on d 0–35) in patient 1, and no prophylactic immunosuppression was administered to patient 2. The maximum non-haematological toxicity observed was grade 2 stomatitis and hyperbilirubinaemia, occurring on d 7 and d 21 after HSCT in patient 1. Both patients achieved a fast and sustained haematological engraftment. Full donor chimaerism could be detected on d +26 in patient 1 and on d +17 in patient 2. Both patients developed acute GVHD grade II involving the skin and liver, as well as limited chronic GVHD. CR was documented on d +25 for patient 1 and on d +49 for patient 2. Both patients remained in CR at the time of writing, 10 and 14 months after the second HSCT with stable donor chimaerism. Figure 1 summarizes the clinical course and the subset chimaerism of patient 2. The clinical course and subset chimaerism in patient 2, with relapsed AML after a first allogeneic bone marrow transplantation (BMT), and who was successfully treated by gemtuzumab ozogamicin and a second allogeneic peripheral blood stem cell transplant (PBSCT) from the same donor. Preparation of cellular subsets and chimaerism analysis were performed as previously described (Thiede et al, 2001). The figure shows the percentage donor chimaerism of the patient against the markers CD4, CD8 and CD34 over a period of 350 d. The time of allogeneic BMT (allo-BMT), relapse, allogeneic PBSCT (allo-PBSCT), and the onset of acute and chronic GVHD are also shown. Sievers et al (2001) reported on 15 patients who underwent allogeneic (n = 10) or autologous (n = 5) HSCT as successful consolidation therapy several weeks after remission induction with GO. In contrast to the reported serious hepatotoxicity [common toxicity criteria (CTC) grade 3–4] in up to 23% of patients, we observed only mild hepatic side-effects in our patients (CTC grade 0–2). However, the cumulative dose of GO in our study was only 9 mg/m2, compared with 18 mg/m2 reported for the pivotal trial (Sievers et al, 2001). Despite poor prognostic factors, the patients in the present study achieved a sustained CR. The use of peripheral PBSC after failure of the first allogeneic BMT in patient 2 might be another cause of the higher antileukaemic efficacy of PBSC when compared with marrow. Furthermore, apoptosis induced by the administration of the anti-CD33 antibody may have induced a potent cytotoxic T-cell response (Selenko et al, 2002). In conclusion, gemtuzumab ozogamicin seems to be a feasible adjunct to minimal conditioning before allogeneic transplantation of haematopoietic stem cells from both related and unrelated donors. This study was supported in part by the Deutsche Krebshilfe (grant no. 70–2755 to CT/MB)." @default.
• W1983456225 created "2016-06-24" @default.
• W1983456225 creator A5005946282 @default.
• W1983456225 creator A5006122560 @default.
• W1983456225 creator A5012098315 @default.
• W1983456225 creator A5017002895 @default.
• W1983456225 creator A5026849709 @default.
• W1983456225 creator A5032718954 @default.
• W1983456225 creator A5060213460 @default.
• W1983456225 creator A5060759169 @default.
• W1983456225 creator A5061229750 @default.
• W1983456225 creator A5074209268 @default.
• W1983456225 date "2003-03-01" @default.
• W1983456225 modified "2023-10-03" @default.
• W1983456225 title "Successful combination of anti-cd33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia" @default.
• W1983456225 cites W1842764967 @default.
• W1983456225 cites W2060159346 @default.
• W1983456225 cites W2081951760 @default.
• W1983456225 cites W2131706663 @default.
• W1983456225 cites W76624571 @default.
• W1983456225 doi "https://doi.org/10.1046/j.1365-2141.2003.04208_4.x" @default.
• W1983456225 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12648086" @default.
• W1983456225 hasPublicationYear "2003" @default.
• W1983456225 type Work @default.
• W1983456225 sameAs 1983456225 @default.
• W1983456225 citedByCount "4" @default.
• W1983456225 countsByYear W19834562252020 @default.
• W1983456225 crossrefType "journal-article" @default.
• W1983456225 hasAuthorship W1983456225A5005946282 @default.
• W1983456225 hasAuthorship W1983456225A5006122560 @default.
• W1983456225 hasAuthorship W1983456225A5012098315 @default.
• W1983456225 hasAuthorship W1983456225A5017002895 @default.
• W1983456225 hasAuthorship W1983456225A5026849709 @default.
• W1983456225 hasAuthorship W1983456225A5032718954 @default.
• W1983456225 hasAuthorship W1983456225A5060213460 @default.
• W1983456225 hasAuthorship W1983456225A5060759169 @default.
• W1983456225 hasAuthorship W1983456225A5061229750 @default.
• W1983456225 hasAuthorship W1983456225A5074209268 @default.
• W1983456225 hasBestOaLocation W19834562251 @default.
• W1983456225 hasConcept C10205521 @default.
• W1983456225 hasConcept C126322002 @default.
• W1983456225 hasConcept C141071460 @default.
• W1983456225 hasConcept C176290653 @default.
• W1983456225 hasConcept C2776694085 @default.
• W1983456225 hasConcept C2776755627 @default.
• W1983456225 hasConcept C2777408962 @default.
• W1983456225 hasConcept C2778245361 @default.
• W1983456225 hasConcept C2778623314 @default.
• W1983456225 hasConcept C2778729363 @default.
• W1983456225 hasConcept C2780611847 @default.
• W1983456225 hasConcept C28328180 @default.
• W1983456225 hasConcept C2911091166 @default.
• W1983456225 hasConcept C54355233 @default.
• W1983456225 hasConcept C71924100 @default.
• W1983456225 hasConcept C86803240 @default.
• W1983456225 hasConceptScore W1983456225C10205521 @default.
• W1983456225 hasConceptScore W1983456225C126322002 @default.
• W1983456225 hasConceptScore W1983456225C141071460 @default.
• W1983456225 hasConceptScore W1983456225C176290653 @default.
• W1983456225 hasConceptScore W1983456225C2776694085 @default.
• W1983456225 hasConceptScore W1983456225C2776755627 @default.
• W1983456225 hasConceptScore W1983456225C2777408962 @default.
• W1983456225 hasConceptScore W1983456225C2778245361 @default.
• W1983456225 hasConceptScore W1983456225C2778623314 @default.
• W1983456225 hasConceptScore W1983456225C2778729363 @default.
• W1983456225 hasConceptScore W1983456225C2780611847 @default.
• W1983456225 hasConceptScore W1983456225C28328180 @default.
• W1983456225 hasConceptScore W1983456225C2911091166 @default.
• W1983456225 hasConceptScore W1983456225C54355233 @default.
• W1983456225 hasConceptScore W1983456225C71924100 @default.
• W1983456225 hasConceptScore W1983456225C86803240 @default.
• W1983456225 hasIssue "6" @default.
• W1983456225 hasLocation W19834562251 @default.
• W1983456225 hasLocation W19834562252 @default.
• W1983456225 hasOpenAccess W1983456225 @default.
• W1983456225 hasPrimaryLocation W19834562251 @default.
• W1983456225 hasRelatedWork W2007433984 @default.
• W1983456225 hasRelatedWork W2040758757 @default.
• W1983456225 hasRelatedWork W2077248326 @default.
• W1983456225 hasRelatedWork W2119104541 @default.
• W1983456225 hasRelatedWork W2320121145 @default.
• W1983456225 hasRelatedWork W2335862939 @default.
• W1983456225 hasRelatedWork W2415822409 @default.
• W1983456225 hasRelatedWork W2521706876 @default.
• W1983456225 hasRelatedWork W2553238430 @default.
• W1983456225 hasRelatedWork W3184391816 @default.
• W1983456225 hasVolume "120" @default.
• W1983456225 isParatext "false" @default.
• W1983456225 isRetracted "false" @default.
• W1983456225 magId "1983456225" @default.
• W1983456225 workType "article" @default.